Proceedings of the National Academy of Sciences · 17 Nov 2026
Intranasal delivery of a ROS-activatable myeloperoxidase inhibitor alleviates Alzheimer’s-like symptoms and pathology
Jing Wangh-index 11, Peilin Cong, Enduo Feng, Matthias W. G. Zeller, Boyu Zhang, Yifan Lv, Negin Jalali Motlagh, Jenny Linnoila, Han Wang, Cuihua Wang, Zhiming Xu, Ke Gao, Qian Chen, Yu Luo, He Wang, Dalong Ni, Lize Xiong, John W. Chenh-index 40
Citations by database
Each database indexes a different set of journals, preprints and books, so they are shown side by side rather than blended.
- OpenCitations0
- Crossref0
- Europe PMC0
Citations per year
The current year is still counting.
- 2026 so far0
Abstract
Chronic neuroinflammation and oxidative stress are important contributors to Alzheimer’s disease (AD). Myeloperoxidase (MPO), a key driver of oxidative inflammation released mainly by activated microglia in the neurodegenerative brain, is a potential therapeutic target to inhibit the neuroinflammatory cascade and oxidative damage in AD, but the underlying mechanisms remain unexplored, and achieving targeted brain delivery of an MPO inhibitor and minimizing systemic effects remain significant challenges. We addressed these limitations by first establishing that genetic deletion of MPO in the 5XFAD mouse model improved memory performance and reduced amyloid deposition, validating MPO as a therapeutic target. We then developed a liposome-encapsulated reactive oxygen species (ROS)-activatable MPO inhibitor (LERAMI). LERAMI uniquely combines targeted delivery with on-demand drug release, utilizing a ROS-sensitive linker to selectively release MPO inhibitors in ROS-rich regions within the AD microenvironment, minimizing off-target effects and systemic toxicity. In the 5XFAD mouse model. By reducing MPO expression and activity, LERAMI significantly improved cognitive performance, accompanied by decreased microglial activation, attenuated oxidative DNA damage, improved synaptic and neuronal density, and reduced amyloid burden. RNA sequencing revealed a robust hippocampal transcriptomic reprogramming, with upregulation of pathways critical for synaptic plasticity, calcium signaling, axon guidance, and neuroprotection, along with downregulation of inflammatory and immune response pathways. These findings demonstrate that targeted ROS-activatable MPO inhibition with LERAMI represents a promising therapeutic strategy for AD and potentially other neuroinflammatory diseases, offering a unique approach to mitigate neuroinflammation, preserve synaptic integrity, and restore cognitive function.
What the data shows
- No database records a citation yet, as is usual for a paper this new.
- John W. Chen has the highest h-index among the authors (40).
Graph
This paper in the middle, its authors and their most-cited papers below, the papers it cites to the left and the papers citing it to the right. The timeline lays every paper out by year.
Select a node for its details. Drag to pan, scroll to zoom, drag a node to move it.
Start with
Cited by 0 papers
Who cites this paper, from open citation data, with Crossref's record of each; the 100 newest when there are more.
References (51)
What it cites, from open citation data, with Crossref's record of each.
Sign in to see 31 more references
A free account opens the rest of the citing papers and references on every paper’s page.